Neuroimmunomodulation

Original Paper

Th1 and Th2 Serum Cytokine Profiles Characterize Patients with Hashimoto’s Thyroiditis (Th1) and Graves’ Disease (Th2)

Phenekos C.a · Vryonidou A.a · Gritzapis A.D.b · Baxevanis C.N.b · Goula M.a · Papamichail M.b

Author affiliations

aDepartment of Endocrinology, Red Cross Hospital, and bImmunology Center, Saint Savas Hospital, Athens, Greece

Keywords: Autoimmune thyroiditisCytokinesFas ligandTh1 and Th2 immune responsesToxic nodular goiter

Related Articles for ""
Neuroimmunomodulation 2004;11:209–213
https://doi.org/10.1159/000078438

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: July 09, 2004
Issue release date: July 2004

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Abstract

Objectives: The aim of this study was to document the pattern of immune response, assessed by the measurement of both Th1 and Th2 serum cytokines, in patients suffering from autoimmune thyroid disease and toxic nodular goiter. Methods: Both Th1 and Th2 serum cytokine levels were assayed in patients suffering from Graves’ disease (GD, n = 25), Hashimoto’s thyroiditis (HT, n = 21), and toxic nodular goiter (TNG, n = 7) and compared with corresponding levels of 25 healthy controls. Serum concentrations of IL-2, IL-1β, INF-γ, TNF-α, IL-12, IL-15, IL-10, IL-18, IL-4 and IL-5 were assayed in fasting serum samples. Results: It was found that patients with HT had higher IL-2 serum levels (12.16 ± 0.66 pg/ml) compared to patients with TNG (9.25 ± 0.84 pg/ml), GD (7.86 ± 0.30 pg/ml) and controls (7.36 ± 0.45 pg/ml; p = 0.0001), higher INF-γ levels (7.60 ± 0.33 pg/ml) compared to patients with TNG (5.77 ± 0.55 pg/ml), GD (5.74 ± 0.24 pg/ml) and controls (5.09 ± 0.27 pg/ml; p = 0.0009), higher IL-12 levels (3.57 ± 0.19 pg/ml) compared to patients with TNG (2.57 ± 0.21 pg/ml), GD (2.48 ± 0.13 pg/ml) and controls (2.59 ± 0.23 pg/ml; p = 0.004), and higher IL-18 levels (27.52 ± 1.75 pg/ml) compared to patients with TNG (18.71 ± 2.24 pg/ml), GD (15.44 ± 1.39 pg/ml) and controls (15.16 ± 1.62 pg/ml; p = 0.0002). In contrast, patients with GD had higher serum levels of IL-4 (4.11 ± 0.33 pg/ml) compared to patients with HT (3.0 ± 0.16; p = 0.02) and higher IL-5 levels (4.22 ± 0.30 pg/ml) compared to patients with TNG (3.21 ± 0.58 pg/ml), HT (2.75 ± 0.16 pg/ml) and controls (2.0 ± 0.19 pg/ml; p = 0.0001). Patients had lower IL-1β serum levels (TNG 2.45 ± 0.20, HT 2.52 ± 0.14, GD 2.68 ± 0.12 pg/ml) compared to controls (3.6 ± 0.20 pg/ml; p = 0.008). Conclusions: The above findings suggest that a Th1 pattern of immune response characteristic of cellular immunity is dominant in HT, whereas the predominance of Th2 cytokines in GD indicates a humoral pattern of immune reaction.

© 2004 S. Karger AG, Basel



Related Articles:

References

  1. Paschke R, Schuppert F, Taton M, Velu T: Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J Endocrinol 1994;141:309–315.
    External Resources
  2. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, Pujol-Borrel R, Jaraquemada D: Single cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto’s and Grave’s diseases. Eur J Immunol 1997;27:3290–3302.
    External Resources
  3. Ajjan RA, Watson PF, Weetman AP: Detection of IL-12, IL-13, and IL-15 messenger ribonucleic acid in the thyroid of patients with autoimmune thyroid disease. J Clin Endocrinol Metab 1997;82:666–669.
    External Resources
  4. Watson PF, Pickerill AP, Davies R, Weetman AP: Analysis of cytokine gene expression in Grave’s disease and multinodular goiter. J Clin Endocrinol Metab 1994;79:355–360.
    External Resources
  5. Weetman AP, Ajjan RA, Watson PF: Cytokines and Grave’s disease. Baillieres Clin Endocrinol Metab 1997;3:481–497.
  6. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM: Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 1999;84:435–439.
    External Resources
  7. Volpe JJ: The pathogenesis of autoimmune thyroid disease. N Engl J Med 1991;325:278–279.
    External Resources
  8. Weetman AP, McGregor AM: Autoimmune thyroid disease: Further development in our understanding. Endocr Rev 1994;15:788–824.
    External Resources
  9. Dayan CM, Daniels GH: Chronic autoimmune thyroiditis. N Engl J Med 1996;335:99–107.
    External Resources
  10. Yamada T, Sato A, Komiya I, Nishimori T, Iti Y, Terao A, Eto S, Tanaka Y: An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Grave’s disease. J Clin Endocrinol Metab 2000;85:2775–2778.
    External Resources
  11. Weetman AP, Rees AJ: Synergistic effects of recombinant tumor necrosis factor-α (TNF) and γ-interferon (γ-INF) on rat thyroidal cell growth and Ia antigen expression. Immunology 1988;63:285–289.
    External Resources
  12. Todd I, Pujot-Borrell R, Hammond LJ, Botazzo GF, Feldmann M: Interferon-γ induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol 1985;11:265–273.
  13. Tandon N, Morgan BP, Weetman AP: Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells. Immunology 1992;75:372–377.
    External Resources
  14. Vargas F, Tolosa E, Sospendra M, et al: Characterization of neural cell adhesion molecule (NCAM) expression in thyroid follicular cells: Induction by cytokines and overexpression in autoimmune glands. Clin Exp Immunol 1994;98:478–488.
    External Resources
  15. McLachlan MS, Prummel MF, Rapoport B: Cell-mediated or humoral immunity in Grave’s ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. J Clin Endocrinol Metab 1994;8:1070–1074.
  16. Wakelkamp JM, Gerding NM, Van der Meer CJ, Prummel MF, Wiersinga MW: Both Th1- and Th2-derived cytokines in serum are elevated in Grave’s ophthalmopathy. Clin Exp Immunol 2000;121:453–457.
    External Resources
  17. Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y: Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2000;85:1194–1199.
    External Resources
  18. Tan GH, Dutton MC, Bahn SR: Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Grave’s ophthalmopathy. J Clin Endocrinol Metab 1996;81:449–452.
    External Resources
  19. Spitzweg C, Morris JC: The immune response to the iodide transporter. Endocrinol Metab Clin North Am 2000;29:389–398.
    External Resources
  20. Seissler J, Wagner S, Schott M, Lettmann M, Feldkamp J, Scherbaum WA, Morgenthaler NG: Low frequency of autoantibodies to the human Na+/I– symporter in patients with autoimmune thyroid disease. J Clin Endocrinol Metab 2000;85:4630–4634.
    External Resources
  21. Fisfalen ME, Palmer EM, Van Seventer AV, Soltani K, Sawai Y, Kaplan E, Hidaka Y, Ober C, Degroot LJ: Thyrotropin-receptor and thyroid peroxidase-specific T cell clones and their cytokine profile in autoimmune thyroid disease. J Clin Endocrinol Metab 1997;82:3655–3663.
    External Resources
  22. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–2357.
    External Resources
  23. Abbas AK, Williams ME, Burnstein HJ, Chang TL, Bossu P, Lichtman AH: Activation and function of CD4+ T cell subsets. Immunol Rev 1991;123:5–22.
    External Resources
  24. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138–146.
    External Resources
  25. Sakaguchi S: Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000;101:455–458.
    External Resources
  26. Shi FD, Ljunggren HG, Sarvetnick N: Innate immunity and auto-immunity: From self-protection to self-destruction. Trends Immunol 2001;22:97–101.
    External Resources
  27. Kallmann BA, Huther M, Tubes M, Feldkamp J, Bertrams J, Gries FA, Lampeter EF, Kolb H: Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Grave’s disease. Diabetes 1997;46:237–243.
    External Resources
  28. Tamaru M, Matsuura B, Onji M: Increased levels of serum interleukin-12 in Grave’s disease. Eur J Endocrinol 1999;141:111–116.
    External Resources
  29. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E: Serum concentrations of proinflammatory cytokines in Grave’s disease: Effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 2000;143:197–202.
    External Resources
  30. Jones BM, Kwok CH, Kung AC: Effect of radioactive iodine therapy on cytokine production in Grave’s disease: Transient increases in interleukin-4 (IL-4), IL-6, IL-10, and tumor necrosis factor-α, with longer term increases in interferon-γ production. J Clin Endocrinol Metab 1999;84:4106–4110.
    External Resources
  31. Trinchieri G: Interleukin-12:A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251–276.
    External Resources
  32. Dinarello CA, Novick D, Puren AJ, Fantuzzi G, Shapiro L, Muhl H, Yoon DY, Reznikov LL, Kim SS, Rubinstein M: Overview of interleukin-18: More than interferon-γ inducing factor. J Leukoc Biol 1998;63:658.
    External Resources
  33. Dremier S, Copee F, Delange F, Vassart G, Dumont JE, Van Sande J: Thyroid autonomy: Mechanism and clinical effects. J Clin Endocrinol Metab 1996;81:4187–4193.
    External Resources
  34. Batteux F, Lores P, Bucchini D, Chiocchia G: Transgenic expression of Fas ligand on thyroid follicular cells prevents autoimmune thyroiditis. J Immunol 2000;164:1681–1688.
    External Resources
  35. Sera N, Kawakami A, Nakashima T, Nakamura H, Imaizumi M, Koji T, Abe Y, Usa T, Tominaga T, Ejima E, Ashizawa K, Yokoyama N, Ishikawa N, Ito K, Eguchi K: Fas/FasL mediated apoptosis of thyrocytes in Grave’s disease. Clin Exp Immunol 2001;124:197–207.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: July 09, 2004
Issue release date: July 2004

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 2

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2004, Vol.11, No. 4

July 2004

Article

Recommend This
TOP